Posttransplantation prevention and treatment of recurrent hepatitis C

Liver Transplantation

Volumn 6, Issue 6 SUPPL. 2, 2000, Pages s35-s40

  Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN; INTERFERON; LAMIVUDINE; LYMPHOCYTE ANTIBODY; RIBAVIRIN; STEROID; TACROLIMUS;

CONFERENCE PAPER; DISEASE COURSE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT INDICATION;

EID: 0033739772     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.18690     Document Type: Conference Paper

References (47)

1. Hepatitis C virus infection following liver transplantation. Review
2. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation
3. Long-term outcome of hepatitis C infection after liver transplantation
4. EASL International Consensus Conference on hepatitis C
5. Recurrent hepatitis C after liver transplantation
6. Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
7. + T cell response in acute hepatitis C
8. Cytokine profile of liver and blood - Derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection
9. Long term outcome of transplantation for hepatitis C
10. Orthotopic liver transplantation for hepatitis C. Outcome, effect of immunosuppression and causes of re-transplantation during an 8 year single centre experience
11. Long-term outcome of hepatitis C virus infection after liver transplantation
12. Treatment for recurrent viral hepatitis after liver transplantation
13. European Collaborative Study on factors influencing outcome after liver transplantation for hepatitis C
14. Pegylated interferon alfa 2B monotherapy is superior to interferon alfa 2B for the treatment of chronic hepatitis C
15. Evaluation of the safety and efficacy of once weekly peglinterferon alfa 2A for chronic hepatitis C. A multinational randomized study
16. Lamivudine prophylaxis against re-infection in liver transplantation for hepatitis B cirrhosis
17. Recurrent HCV infection following OLTx: The role of early post OLTx interferon treatment
18. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients
19. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
20. Prophylaxis against HCV recurrence after liver transplantation. Effect of interferon and ribavirin combination
21. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients
22. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation
23. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
24. Effectiveness of early alpha interferon therapy for hepatitis C virus infection recurrence after liver transplantation
25. Outcome of liver transplant recipients treated with interferon alpha monotherapy for recurrent hepatitis C
26. Efficacy and safety of alpha interferon for hepatitis C after liver transplantation
27. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation
28. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients
29. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation
30. Ribavirin therapy for hepatitis C infection following liver transplantation
31. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation
32. Treatment of recurrent hepatitis C virus infection after liver transplantation with IFN and ribavirin
33. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients
34. Interferon/ribavirin therapy for recurrent hepatitis C after liver transplantation
35. Quantitation of hepatitis C virus RNA in liver transplant recipients
36. A longitudinal analysis of hepatitis C virus replication following liver transplantation
37. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation
38. The outcome of hepatitis C virus infection after liver transplantation - Is it influenced by the type of immunosuppression?
39. Severe or multiple rejection episodes is associated with early recurrence of hepatitis C after orthotopic liver transplantation
40. Longitudinal variation in HCV viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens
41. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
42. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation
43. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus
44. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
45. A pilot study of immunosuppressive monotherapy in liver transplantation: Tacrolimus versus microemulsified cyclosporin
46. Predictive factors of histological outcome in post transplant HCV infection
47. Histological grading and staging of chronic hepatitis